ライフサイエンスコーパス: VLP

1 VLP DNA-seq provides a comprehensive landscape of LTR re

2 VLP vaccination led to a significant increase in the fre

3 VLP-based vaccines showed significantly better neutraliz

4 8 or integrin blockade severely limits HIV-1 VLP spread onto FDC networks.

5 and an RGD motif, MFG-E8 helps target HIV-1 VLPs to alphav integrin bearing SMs.

6 We further show that SARS-CoV-2 VLPs dried in ambient conditions can retain their struct

7 uorescently and APEX2-labeling of SARS-CoV-2 VLPs for the evaluation of mechanisms of viral budding a

8 The assembled SARS-CoV-2 VLPs possess S protein spikes on particle exterior, maki

9 issociation constants (KD < 10 nM) for GII.4 VLP.

10 For use as a tetravalent vaccine, DENV1-4 VLPs elicited high levels of neutralization activity aga

11 particle interaction studies of Sydney GII.4 VLPs with glycosphingolipid-containing HIE membranes, bo

12 ctron microscopy reconstruction of the T = 4 VLPs assembled in the presence of one of the RNAs reveal

13 LPs) against pig gastric mucin (PGM) using 4 VLPs that represent different GII.4 norovirus variants i

14 We created recombinant DENV1 to -4 (DENV1-4) VLPs by coexpressing precursor membrane (prM) and envelo

15 vaccination of 15 ug each of GI.1 and GII.4c VLPs with Al(OH)3.

16 type VLPs, respectively, and 50 ug of GII.4c VLPs) with MPL and Al(OH)3.

17 re 10- to 12-fold higher than titers after a VLP prime and boost of RSV-naive animals or after two co

18 We demonstrated that mice maintained on a VLP diet succumb to lethal challenge at greater rates th

19 This study demonstrates that a VLP vaccine candidate containing a stabilized prefusion

20 binding affinity for four synbodies against VLPs from multiple GI and GII genotypes and found that t

21 AF) nanoparticle and encephalitic alphavirus VLP-based vaccines.

22 h GFP in the cytosol and ER without altering VLP formation or GFP fluorescence.

23 e packaged in one VLP and mixed with another VLP displaying the antigen prior to administration in vi

24 hese results show that the Tag/Catcher AP205 VLP system can be exploited to make a combinatorial vacc

25 d Pfs47 antigen to Acinetobacter phage AP205-VLP using the SpyCatcher:SpyTag adaptor system.

26 that conjugating the Pfs47 antigen to AP205-VLP significantly enhanced antigenicity and confirm the

27 antity of antibodies, while SpyCatcher-AP205-VLPs elicited the highest quality anti-Pfs25 antibodies

28 d, as does the ventrolateral posterior area (VLP) in marmosets and the dorsolateral posterior area (D

29 gh genome-free PV ECs have been expressed as VLPs in a variety of systems, their inherent antigenic i

30 Stabilized ECs, expressed recombinantly as VLPs, could be ideal candidate vaccines for a polio-free

31 To assess VLPs with improved compatibility with these techniques,

32 Vaccination of rhesus macaques with bivalent VLPs generated strong humoral immune responses, includin

33 there was no virus-induced mortality in both VLP and AP groups of mice when either group was immunize

34 l anti-F protein IgG antibody levels in both VLP-immunized animals were similar.

35 Both VLPs efficiently reached the same draining lymph node wh

36 Membrane disruption by VLP is insensitive to pH, but unassembled capsid protein

37 I) antibody titers than antisera elicited by VLP vaccines with wild-type HA VLPs in preimmune ferrets

38 We also found that antibodies induced by VLPs containing different versions of the prefusion F pr

39 the offspring of dams immunized with DS-Cav1 VLPs.

40 Intraperitoneal injections of CD4-CCR5-VLP produced only subneutralizing plasma concentrations

41 CD4-VLPs also neutralized patient-derived viral isolates tha

42 based inhibitors are ineffective against CD4-VLPs.

43 In neutralization assays, CD4-VLPs were >12,000-fold more potent than sCD4 and CD4-Ig

44 remained sensitive to neutralization by CD4-VLPs in vitro.

45 ent clusters of membrane-associated CD4 (CD4-VLPs) to permit high-avidity binding of trimeric HIV-1 e

46 Moreover, CD4-VLPs potently neutralized viral swarms that were complet

47 itro evolution studies demonstrated that CD4-VLPs effectively controlled HIV-1 replication at neutral

48 ssess the vaccine VRC-CHKVLP059-00-VP (CHIKV VLP).

49 Notably, sera produced against chimeric VLPs that presented swapped structural domains, shell an

50 long-lasting protective efficacy of chimeric VLPs (cVLPs) containing influenza HA and GPI-anchored CC

51 Three distinct combinatorial VLPs were produced displaying one, two or five concatena

52 AP205-Pfs47 complexes (VLP-P47) formed particles of ~22 nm diameter that reacte

53 d RSV infection or a postfusion F-containing VLP cannot.

54 while an immunization with post-F-containing VLPs or a second RSV infection only weakly stimulated NA

55 nt combinations of Capsid protein containing VLPs either as monovalent, bivalent or tetravalent formu

56 We established an approach for coupling VLPs to diverse antigen symmetries.

57 us-like particles (VLPs), and that defective VLPs with NP-Ct deletions are significantly reduced in v

58 iPALM imaging on immobilized HIV Gag-Dendra2 VLPs and demonstrate that we can localize and count 900-

59 vious attempts of other groups to use dengue VLPs resulted in generally poor yields.

60 We coupled the computer-designed VLP not only to monomers (SARS-CoV-2) but also to cyclic

61 rt-read and long-read sequencing of VLP DNA (VLP DNA-seq) revealed a comprehensive catalog of active

62 be incorporated as a passenger into F-driven VLPs, provided that the F protein was competent for endo

63 an those with the DNA vaccines, with C-prM-E VLPs giving slightly higher titers than those with prM-E

64 The prM-E VLPs induced a strong neutralizing antibody response in

65 The superiority of C-prM-E VLPs suggests that inclusion of capsid may have benefits

66 Furthermore, C-prM-E and prM-E VLPs were tested as vaccine candidates in mice and compa

67 slightly higher titers than those with prM-E VLPs.

68 ag-Dendra2 proteins incorporated within each VLP.

69 ults demonstrate that a novel bivalent Ebola VLP vaccine elicits strong humoral and cellular immune r

70 Immunization of rabbits with bivalent Ebola VLPs produced antibodies that neutralized all four patho

71 SpyCatcher003 enabled efficient VLP conjugation and extreme thermal resilience.

72 as sufficient for generating VLPs, efficient VLP production from the C-prM-E construct could be achie

73 that received two immunizations with either VLP-P47 (VLP-P47/VLP-P47) or the Pfs47 monomer (P47/P47)

74 High-Env VLPs, or hVLPs, were shown to be monodisperse and to dis

75 IV Env or a virus-like particle form of Env (VLP) induces potent and durable Env-specific antibody re

76 w that ectopic YAP expression inhibits eVP40 VLP egress and that Amot co-expression rescues budding o

77 Amot co-expression rescues budding of eVP40 VLPs in a dose-dependent and PPxY-dependent manner.

78 te efficient production and release of eVP40 VLPs.

79 ed vaccines or help to re-formulate existing VLP vaccines not naturally carrying immunostimulatory se

80 Importantly, the offspring of UC-3 F VLP-immunized dams showed significant protection from lu

81 ted by a pre-F VLP boost but not by a post-F VLP boost or a second RSV infection.IMPORTANCE Humans ma

82 Furthermore, single pre-F or post-F VLP immunization of animals previously infected (primed)

83 that can be efficiently activated by a pre-F VLP boost but not by a post-F VLP boost or a second RSV

84 Immunization with UC-3 F VLPs also induced durable levels of high-titer neutraliz

85 ccines in cotton rats and report that UC-3 F VLPs significantly increased the neutralizing antibody (

86 nged offspring of dams immunized with UC-3 F VLPs than in the lungs of the RSV-challenged offspring o

87 offspring of the dams immunized with UC-3 F VLPs were significantly higher than those in the sera of

88 lternative pre-F VLPs, the UC-2 F and UC-3 F VLPs, stimulated in mice higher titers of neutralizing a

89 rs of neutralizing antibodies than DS-Cav1 F VLPs (M.

90 rison of these two pre-F VLPs with DS-Cav1 F VLPs as maternal vaccines in cotton rats and report that

91 iters in pregnant dams compared to DS-Cav1 F VLPs.

92 d offspring of dams immunized with DS-Cav1 F VLPs.

93 proteins, including the prototype DS-Cav1 F VLPs.

94 we describe a comparison of these two pre-F VLPs with DS-Cav1 F VLPs as maternal vaccines in cotton

95 Two of these alternative pre-F VLPs, the UC-2 F and UC-3 F VLPs, stimulated in mice hig

96 This meant there were (1) fewer VLPs with no antibodies bound, which is an important con

97 have benefits for ZIKV and other flaviviral VLP vaccines.

98 ndocytic F trafficking that is important for VLP assembly, not proteolytic F cleavage.

99 nal viral protein interactions important for VLP formation, we improve our understanding of the viral

100 g led to failure of F to function with M for VLP assembly.

101 Wild-type F functioned normally for VLP assembly even when its cleavage was prevented with a

102 lated homologous fusion peptide-mutated (FP)-VLPs consistently showed higher positive-to-negative val

103 n reach up to 95% with the combination of FP-VLP and NS1 assays.

104 l, the sensitivity and specificity of the FP-VLP-MAC-ELISA and the NS1-MAC-ELISA were each higher tha

105 Therefore, we used DENV-2/3 and ZIKV FP-VLPs to develop a novel, serological algorithm for diffe

106 (CPMV) (RNA containing) and eCPMV (RNA-free VLPs) produced from two expression systems (agrobacteriu

107 igos do not interact with preformed RNA-free VLPs, so their effects must occur during particle assemb

108 parable to the curvature values derived from VLP size distributions.

109 Purified IgG from VLP-P47/P47 mice had strong TRA (83-98%) at concentratio

110 comparing responses to those resulting from VLP immunization of RSV-naive animals.

111 onstruct alone was sufficient for generating VLPs, efficient VLP production from the C-prM-E construc

112 rmulations (ie, 15 or 50 ug of GI.1 genotype VLPs, respectively, and 50 ug of GII.4c VLPs) with MPL a

113 a elicited by VLP vaccines with wild-type HA VLPs in preimmune ferrets.

114 r period against MD145, Grimsby, and Houston VLPs.

115 00 Dendra2 molecules within each immobilized VLP with a single-molecule localization precision better

116 w dynamics within the lattice of immobilized VLPs in the timescale of 10-100 s.

117 dra2 lattice within the lumen of immobilized VLPs.

118 onsensus in packaging and delivering CpGs in VLP-based vaccines is that both adjuvants and antigens s

119 ongly blocks PR-catalyzed CA-SP1 cleavage in VLPs and blocks conversion of VLPs to tubular CA assembl

120 Our stable cell lines secreting individual VLPs provide a flexible yet scalable platform convenient

121 While HA acylation did not influence VLP shape, lipid composition, or HA lateral spacing, acy

122 to influenza VLPs without CCL28 or influenza VLPs physically mixed with sCCL28 (soluble) in mice.

123 month post-vaccination compared to influenza VLPs without CCL28 or influenza VLPs physically mixed wi

124 formation enhanced the recruitment of G into VLPs.

125 way to monitor disassembly of (19)F-labeled VLPs derived from bacteriophage Qbeta by (19)F NMR.

126 ssNMR chemical shifts of segmentally labeled VLPs with and without BVM are very similar, indicating t

127 These novel proteins distinguish Lh from Lb VLPs; notably, some proteins specific to Lh VLPs possess

128 tructure-informed analyses of an abundant Lh VLP surface and spike-tip protein, p40, reveal similarit

129 Our studies suggest that Lh VLPs represent a new class of extracellular organelles a

130 VLPs; notably, some proteins specific to Lh VLPs possess sequence similarities with bacterial secret

131 mphatic system and show that also non-linked VLPs are efficiently co-delivered to the same APCs in ly

132 on of Toll-like receptor ligands, which many VLPs naturally package.

133 ing modes are observed with the fully mature VLP, with one Mxra8 binding with unique contacts.

134 beneficial when designing precision medicine VLP-based vaccines or help to re-formulate existing VLP

135 Our data show that MrNV VLPs package nucleic acids in a manner reminiscent of ot

136 ugated to the surface of a bacteriophage MS2 VLP.

137 The use of mutant VLPs confirmed that the interaction nfGNPs-VLPs is not m

138 e genomic RNA, and virus-like nanoparticles (VLPs) based on the empty CPMV (eCPMV) virion.

139 t VLPs confirmed that the interaction nfGNPs-VLPs is not mediated by the opposing superficial electro

140 eriments suggested that the nature of nfGNPs-VLPs interaction is non-covalent.

141 increasing ethanol concentrations on nfGNPs-VLPs complexes suggested hydrophobic interactions as the

142 Therefore, the nfGNPs-VLPs interaction described here should facilitate the de

143 ls of antibodies to both candidate norovirus VLP formulations persisted above baseline levels for at

144 Although norovirus VLPs have been thought to exist in a single-sized assemb

145 This is the first time norovirus VLPs have been shown to interact specifically with secre

146 he extent of conjugation and modification of VLP based therapeutics.

147 ghput short-read and long-read sequencing of VLP DNA (VLP DNA-seq) revealed a comprehensive catalog o

148 elf-association represents the first step of VLP assembly and, in concert with scaffolding along the

149 ng ZIKV prM-E that produces large amounts of VLPs in the supernatant and a ZIKV C-prM-E cell line tha

150 sm of Drosophila [6], but the composition of VLPs and their biotic nature have remained mysterious.

151 P1 cleavage in VLPs and blocks conversion of VLPs to tubular CA assemblies, (15)N and (13)C ssNMR che

152 s consistent with the preferred curvature of VLPs being a consequence of interaction of CP with RNA-i

153 nfection, immunization with a single dose of VLPs containing a conformation-stabilized prefusion F pr

154 Moreover, if the F-driven formation of VLPs occurs through interactions with host cell machiner

155 e mainly through the effective inhibition of VLPs' binding to HBGA receptors and moderate inhibition

156 to HBGA receptors and moderate inhibition of VLPs' binding to their antibodies, without affecting the

157 ificant lattice dynamics within the lumen of VLPs.

158 structure of E to increase the production of VLPs in mammalian cells.

159 highly effective to inhibit both strains of VLPs' bindings to histo-blood group antigens (HBGA) rece

160 Furthermore, our data on VLP and, by hypothesis, virus suggests that HA acylation

161 of CDots also exhibited inhibitory effect on VLP's binding to their respective antibodies, but much l

162 Specifically, Fel d 1 on VLPs induced strongly increased protective IgG responses

163 binding, repetitively displayed allergen on VLPs failed to cause mast cell activation.

164 te that repetitively displaying allergens on VLPs increases their immunogenicity while reducing their

165 ivation in its free form versus displayed on VLPs and we performed allergen binding studies by surfac

166 ized mast cells whereas Fel d 1 displayed on VLPs fails to induce mast cell activation.

167 have shown that CpGs can be packaged in one VLP and mixed with another VLP displaying the antigen pr

168 nd physically distinct from M-only or F-only VLPs.

169 while strongly discriminating against other VLP types.

170 Our VLP-based platform provides a source for a ZIKV vaccine

171 eived two immunizations with either VLP-P47 (VLP-P47/VLP-P47) or the Pfs47 monomer (P47/P47).

172 o immunizations with either VLP-P47 (VLP-P47/VLP-P47) or the Pfs47 monomer (P47/P47).

173 e developed a potential Virus Like Particle (VLP) based multivalent vaccine candidate to target these

174 We have devised a virus like particle (VLP) carrier based on the hepatitis B core antigen (HBcA

175 -EM) structure of a B19 virus-like particle (VLP) complexed with the antigen-binding fragment (Fab) o

176 Virus-like particle (VLP) conjugates are being developed for biomedical appli

177 ed to a cucumber mosaic virus-like particle (VLP) containing a universal T cell epitope (CuMV(TT) ) u

178 covalently coupled to a virus-like particle (VLP) derived from cucumber mosaic virus containing a tet

179 the AP205 capsid-based virus-like particle (VLP) designed to simultaneously display two clinically r

180 ffinity ligands using a virus-like particle (VLP) from the 2006 GII.4 Minerva strain of norovirus.

181 sed P. vivax vaccine, a virus-like particle (VLP) known as Rv21, able to provide 100% sterile protect

182 rated, open-source, MS2-virus-like particle (VLP) SARS-CoV-2 standard, we validate RNA extraction and

183 .1 and GII.4c norovirus virus-like particle (VLP) vaccine candidate adjuvanted with alum and monophos

184 da's bivalent norovirus virus-like particle (VLP) vaccine candidate in 50 healthy 18- to 49-year-olds

185 ization, with novel RSV virus-like particle (VLP) vaccine candidates containing stabilized prefusion

186 uation of a Pfs47-based virus-like particle (VLP) vaccine generated by conjugating our 58 amino acid

187 te the nanoparticle and virus-like particle (VLP) vaccine molecules from host cell proteins and other

188 valent, spherical Ebola virus-like particle (VLP) vaccine that incorporates glycoproteins (GPs) from

189 accinating ferrets with virus-like particle (VLP) vaccines expressing COBRA HA proteins elicited anti

190 s, were vaccinated with virus-like particle (VLP) vaccines expressing either an HA from a wild-type H

191 n and use of virus-free virus-like particle (VLP) vaccines that mimic the "empty" capsids (ECs) norma

192 compared five different virus-like particle (VLP)-associated, mutation-stabilized prefusion F (pre-F)

193 We used a virus-like particle (VLP)-based approach to develop a vaccine and a microneut

194 istration of 2 bivalent virus-like particle (VLP)-based candidate norovirus vaccine formulations in a

195 loped ZIKV subunit- and virus-like particle (VLP)-based vaccines displaying E in its wild-type form o

196 in the interior of the virus-like particle (VLP).

197 other is a more complex virus-like particle (VLP-cvD).

198 ted to bind the Type 16 virus-like-particle (VLP) formed by the self-assembling capsid protein L1.

199 We used virus-like particles (VLP) to study the effect of acylation on morphology, pro

200 d G protein-containing virus-like particles (VLP), comparing responses to those resulting from VLP im

201 titer (BT50) values of virus-like particles (VLPs) against pig gastric mucin (PGM) using 4 VLPs that

202 lating egress of eVP40 virus-like particles (VLPs) and for egress and spread of authentic EBOV.

203 ction between HPV16 L1 virus-like particles (VLPs) and non-functionalized GNPs (nfGNPs) resulting in

204 ectious wild-type (wt) virus-like particles (VLPs) and soluble nonstructural protein 1 (NS1) in the s

205 n standards were used: Virus-Like Particles (VLPs) and synthetic beads with a mean diameter of 53nm a

206 Virus-like particles (VLPs) are ideal platforms for such 3D vaccines, as they

207 Virus-like particles (VLPs) are important vaccine platforms against pathogenic

208 Virus-like particles (VLPs) are stable protein cages derived from virus coats.

209 when using viruses or virus-like particles (VLPs) as an immunotherapeutic agent.

210 e demonstrate that HIV virus-like particles (VLPs) assembled by the viral protein Gag and tagged at i

211 Selected huNoV-like particles (VLPs) bound the glycocalyx of HIOs with matched HBGA phe

212 es the uptake of HIV-1 viral-like particles (VLPs) by FDCs and B cells in mouse lymph node.

213 -infectious SARS-CoV-2 virus like particles (VLPs) can be assembled by co-expressing the viral protei

214 Virus-like particles (VLPs) can be used as nano-carriers and antigen-display s

215 ution structure of B19 virus-like particles (VLPs) complexed with the Fab of a human neutralizing ant

216 red N termini, such as virus-like particles (VLPs) composed of the well-studied MS2 bacteriophage coa

217 p55 (protein) or with virus-like particles (VLPs) containing SIVmac239 Env and Gag.

218 ecombinantly expressed virus-like particles (VLPs) could address these inherent problems.

219 e were vaccinated with virus-like particles (VLPs) expressing one of the 12 modified HA antigens (des

220 ag/Gag-Pol-Nef-derived virus-like particles (VLPs) from clade C and were used as the prime, with reco

221 We purified virus-like particles (VLPs) from ddm1 and ddm1rdr6 mutants in which genomic RN

222 their ability to form virus-like particles (VLPs) from human cells to form a competent system for BS

223 Spiked virus-like particles (VLPs) in wasp venom have clearly been linked to wasps' s

224 tivated EBOV and Ebola virus-like particles (VLPs) induced NF-kappaB activation mediated by Toll-like

225 repetitive fashion on virus-like particles (VLPs) may fulfill these criteria.

226 the structure of MrNV virus-like particles (VLPs) produced by recombinant expression of the capsid p

227 Antigenicity of virus-like particles (VLPs) representative of clusters I, II, and IIIb GII.17

228 ne sera raised against virus-like particles (VLPs) representing different genotypes showed highly-spe

229 oordinated assembly of virus-like particles (VLPs) that were morphologically and physically distinct

230 ility of the resulting virus-like particles (VLPs) to encapsidate mutant STNV-1 RNAs expected to have

231 the affinity of HuNoV virus-like particles (VLPs) to lipid vesicles produced from the individual HIE

232 ized (~22-nm diameter) virus-like particles (VLPs) when mixed with cowpea chlorotic mottle virus CP,

233 oduction of infectious virus-like particles (VLPs), and that defective VLPs with NP-Ct deletions are

234 ture of the M. spretus virus-like particles (VLPs), determined using cryo-electron microscopy, showed

235 surements on spherical virus-like particles (VLPs), facilitated by segmental isotopic labeling, that

236 and, using delivery by virus-like particles (VLPs), that Vpr alone is sufficient for REAF degradation

237 engue vaccine by using virus-like particles (VLPs), which are noninfectious because they lack the vir

238 ovirus outbreak strain virus-like particles (VLPs).

239 neously assembles into virus-like particles (VLPs).

240 erisation scaffolds or virus like particles (VLPs).

241 packaged within Qbeta virus-like particles (VLPs).

242 nduce the formation of virus-like particles (VLPs).

243 cco mosaic virus (TMV) virus-like particles (VLPs).

244 nd their corresponding virus like particles (VLPs).

245 disruption assays, we demonstrate that PCV2 VLP, unassembled capsid, and ARM peptide possess the abi

246 V prM-E proteins that constitutively produce VLPs as well as a cell line expressing ZIKV C-prM-E prot

247 Feeding pigs with very-low protein (VLP) diets while supplemented with limiting amino acids

248 ts following validated laboratory protocols (VLPs), and results were recorded in the laboratory infor

249 ns and verified lattice dynamics in purified VLPs incorporating 10% Gag-SNAP, 10% Gag-Halo, and 80% G

250 ggregation and the stabilization of purified VLPs.

251 he production of synthetically stabilized PV VLPs in plants.

252 mbination of RNAi scaffold design with Qbeta VLP packaging is demonstrated to be target-specific and

253 demonstrate that chemically-conjugated Qbeta VLPs elicited the highest quantity of antibodies, while

254 ligase that ubiquitinates VP40 and regulates VLP egress.

255 tegy extracellular vesicle (MSEV) to replace VLP.

256 stable cell lines that continuously secrete VLPs in the culture supernatants.

257 The 293 T stable cell lines secreting VLPs were adapted to grow in suspension cultures to faci

258 nd that M could no longer induce significant VLP release but retained the ability to be incorporated

259 e flanking spacer peptide SP1 that stabilize VLPs, but much less is known about the assembly pathway

260 stability and postulate that such stabilized VLPs could be used as novel vaccines.

261 e applied as candidates to synthesize stable VLPs as future genome-free poliovirus vaccines.

262 this study was to determine if supplementing VLP diets with branched-chain AA (BCAA) would reverse th

263 Thus, supplementing VLP diets with BCAA temporarily annuls the adverse effec

264 n with that of the soluble dimer and support VLP-cvD as a promising ZIKV vaccine.IMPORTANCE Infection

265 ategy for the creation of putative, targeted-VLP delivery systems.

266 Interestingly, the potential tetravalent VLP vaccine candidate provided strong neutralizing antib

267 against more H1N1 viruses in the panel than VLP vaccines expressing wild-type HA proteins.

268 Our proteomics studies reveal that VLPs lack viral coat proteins but possess a pharmacopoei

269 Immunization studies in mice showed that VLPs generated higher neutralizing antibody titers than

270 antigens, we successfully conjugated tHBcAg VLPs to the HIV capsid protein P24 in the cytosol.

271 ient when SpyCatcher was displayed on tHBcAg VLPs instead of being fused to GFP.

272 We show that tHBcAg VLPs could be successfully conjugated with GFP in the cy

273 optimal to display SpyCatcher on the tHBcAg VLPs and SpyTag on the binding partner.

274 jugation of tandem Hepatitis B core (tHBcAg) VLPs and the model antigen GFP in vivo in Nicotiana bent

275 The VLP-cvD was the most effective, and we believe it repres

276 The VLP-RNAi assembles upon co-expression of CP and the RNAi

277 To facilitate the VLP platform, we generated a stable cell line expressing

278 move the undesired genomic material from the VLP preparation and observed that, for the samples where

279 tenated RG1 epitopes without obstructing the VLP's capacity to form.

280 r images, and results were compared with the VLP.

281 son "suicide" by auto-integration within the VLP.

282 ra2 have the same morphology and size as the VLPs assembled using only HIV Gag.

283 ralization antibody responses induced by the VLPs were significantly higher than those with DNA or re

284 ze (~28 nm in diameter) is preferred for the VLPs formed with such RNAs.

285 Moreover, inclusion of Capsid in the VLPs provides an additional viral protein leading to an

286 r data demonstrated a higher efficacy of the VLPs in comparison with that of the soluble dimer and su

287 ticipate in the arrangement of nfGNPs on the VLPs surface.

288 Addition of disuccinimidyl suberate to the VLPs completely abrogated these dynamics as observed in

289 l stability with the largest length, for TMV VLP to date.

290 The robust nature of this TMV VLP allows for reducer-free synthesis of excellent elect

291 Conjugation of peptides or whole proteins to VLPs can be achieved using different methods such as the

292 to disrupt endosomal-like membranes, whereas VLP lacking the ARM sequence does not possess this capab

293 bition of GFP expression in human cells with VLP-RNAi.

294 Mice immunized with VLP-P47 followed by a boost with Pfs47 monomer induced s

295 Mice were vaccinated with VLPs expressing HA antigens that lacked a glycosylation

296 Both ZIKV-derived wt-VLP- and NS1-MAC-ELISAs were found to have similar sensi

297 sitive-to-negative values than homologous wt-VLPs.

298 HBcAg-zDIII VLPs are shown to be highly immunogenic, as two doses el

299 Notably, HBcAg-zDIII VLPs-elicited antibodies did not enhance the infection o

300 also demonstrated that the Zika virus (ZIKV) VLP production level was enhanced by introducing the sam